Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

genomeweb
360dx

Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

Oct 21, 2004

NEW YORK, Oct. 21 (GenomeWeb News) - Genaissance Pharmaceuticals lowered by around 20 percent its year-end revenue expectations, to between $20 million and $21 million from $25 million, the company said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

GenMark Diagnostics Q4 Revenues Rise 21 Percent
Exact Sciences' Q4 Revenues Up 64 Percent
Genome Organization Variation Uncovered With Molecular Mapping Methods
Genomic Health Q4 Revenues Rise 22 Percent; International Efforts Expected to Push 2019 Growth
Agilent Q1 Revenues Up 6 Percent
Murrieta to Promote SeqOnce Sample Prep Tech at Incubator Facility

The Scan

No More

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Dunno What Those Do

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

HeLa Variety

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

This Week in Nature

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Main menu